Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal trial of RTB101 in high-risk elderly patients with respiratory tract infections

Trial Profile

A pivotal trial of RTB101 in high-risk elderly patients with respiratory tract infections

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2018

At a glance

  • Drugs Dactolisib (Primary)
  • Indications Influenza virus infections; Respiratory tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors resTORbio
  • Most Recent Events

    • 23 Aug 2018 New trial record
    • 09 Aug 2018 According to a resTORbio media release, the company is planning to start the pivotal programm in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top